Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Ingredients

Alland & Robert marks 141 years with innovation-driven expansion into Asia and the Middle East

At Gulfood Manufacturing 2025, Alland & Robert will showcase its latest sustainable gum solutions — Syndeo Gelling and Beyond Acacia — as the company reinforces its global leadership and launches new R&D consulting services for food and cosmetic manufacturers
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now